The CBX5 Knockout MES-OV Polyclonal Cells consist of a CRISPR/Cas9-edited polyclonal population with targeted disruption of the CBX5 gene in MES-OV human ovarian carcinoma cells. This product provides a mixed pool of cells carrying diverse loss-of-function alleles, avoiding clonal selection biases and offering a robust model for HP1alpha deficiency. The polyclonal format is ideal for experiments requiring bulk analysis of CBX5 depletion.
MES-OV is an epithelial cell line derived from ascites of an ovarian adenocarcinoma patient, widely used as a model for high-grade serous ovarian cancer. These cells exhibit hallmark features of the disease, including genomic instability and epigenetic dysregulation, making them a suitable platform to study chromatin-mediated silencing in a tumor-relevant context.
CBX5 (HP1alpha) binds methylated histone H3 at lysine 9 (H3K9me3) via its chromodomain, oligomerizes, and compacts chromatin to enforce transcriptional silencing. It functions downstream of H3K9 methyltransferases SUV39H1 and SETDB1, and its activity is regulated by CK2 and PKA phosphorylation. CBX5 forms repressive complexes with TRIM28/KAP1, CHAF1A, and the Lamin B receptor, and its silencing targets include LINE-1 retrotransposons, pericentromeric satellite repeats, and multiple tumor suppressor genes. Thus, CBX5 integrates epigenetic signals to control heterochromatin maintenance, gene silencing, and genome stability.
In ovarian cancer, aberrant CBX5-mediated silencing can drive tumorigenesis by repressing critical tumor suppressors. Knockout of CBX5 in MES-OV cells allows researchers to examine the consequences of HP1alpha loss on H3K9me3-dependent chromatin compaction and gene derepression. This polyclonal knockout pool captures cellular heterogeneity, enabling studies of variable responses to epigenetic disruption that are pertinent to therapy resistance.
Typical applications include western blotting for CBX5, ChIP-qPCR for H3K9me3 levels, RT-qPCR of reactivated target genes, and immunofluorescence of heterochromatin foci. Proliferation and drug sensitivity assays can further elucidate CBX5’s role in ovarian cancer cell growth and treatment response. Together, these approaches support drug target validation and mechanistic studies of epigenetic silencing. For inquiries, contact Ascent Research.
